ConductScience.org, home

Disease · MONDO_0000607

Drugs105

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
ROMIDEPSINCHEMBL343448ProteinApprovalDailyMed and TTD151313Drugs and targets
BEXAROTENECHEMBL1023Small moleculeApprovalDailyMed, EMA Human Drugs, PMDA and TTD151111Drugs and targets
VORINOSTATCHEMBL98Small moleculeApprovalDailyMed, PMDA and TTD141111Drugs and targets
DENILEUKIN DIFTITOXCHEMBL1201550ProteinApprovalDailyMed and PMDA977Drugs and targets
METHOXSALENCHEMBL416Small moleculeApprovalTTD322Drugs and targets
MECHLORETHAMINE HYDROCHLORIDECHEMBL1201001Small moleculeApprovalDailyMed100Drugs and targets
MOGAMULIZUMABCHEMBL1743041AntibodyPhase 3ClinicalTrials.gov and TTD121111Drugs and targets
BRENTUXIMAB VEDOTINCHEMBL1742994Antibody drug conjugatePhase 3TTD877Drugs and targets
LENALIDOMIDECHEMBL848Small moleculePhase 3ClinicalTrials.gov666Drugs and targets
BORTEZOMIBCHEMBL325041Small moleculePhase 3ClinicalTrials.gov444Drugs and targets
HYPERICINCHEMBL286494Small moleculePhase 3ClinicalTrials.gov and TTD533Drugs and targets
PEMBROLIZUMABCHEMBL3137343AntibodyPhase 2ClinicalTrials.gov777Drugs and targets
CYCLOPHOSPHAMIDECHEMBL1200796Small moleculePhase 2ClinicalTrials.gov666Drugs and targets
DOXORUBICINCHEMBL53463Small moleculePhase 2ClinicalTrials.gov444Drugs and targets
PANOBINOSTATCHEMBL483254Small moleculePhase 2ClinicalTrials.gov443Drugs and targets
PREDNISONECHEMBL635Small moleculePhase 2ClinicalTrials.gov444Drugs and targets
FORODESINECHEMBL218291Small moleculePhase 2ClinicalTrials.gov433Drugs and targets
FLUDARABINECHEMBL1568Small moleculePhase 2ClinicalTrials.gov333Drugs and targets
MECHLORETHAMINECHEMBL427Small moleculePhase 2ClinicalTrials.gov331Drugs and targets
VINCRISTINECHEMBL90555Small moleculePhase 2ClinicalTrials.gov333Drugs and targets

diseases-2026-09-18-0.1.0

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000607/drugs